The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation.
Br J Haematol
; 204(2): 612-622, 2024 02.
Article
em En
| MEDLINE
| ID: mdl-37857379
ABSTRACT
Allogeneic haematopoietic stem cell transplantation (HCT) is the curative treatment for myelodysplastic syndrome with a complex karyotype (CK-MDS). However, only a few studies have been limited to patients with CK-MDS undergoing allogeneic HCT. This study aimed to identify the risk factors for patients with CK-MDS undergoing allogeneic HCT. We included 691 patients with CK-MDS who received their first allogeneic HCT. The overall survival (OS) was the primary end-point, estimated using the Kaplan-Meier method. Prognostic factors were identified using a Cox proportional hazards model. The 3-year OS was 29.8% (95% confidence interval [CI] 26.3-33.3). In the multivariable analysis, older age (hazard ratio [HR] 1.44, 95% CI 1.11-1.88), male sex (HR 1.38, 95% CI 1.11-1.71), poor haematopoietic cell transplant comorbidity index (HR 1.47, 95% CI 1.20-1.81), red blood cell transfusion requirement (HR 1.58, 95% CI 1.13-2.20), platelet transfusion requirement (HR 1.85, 95% CI 1.46-2.35), not-complete remission (HR 1.55, 95% CI 1.16-2.06), a high number of karyotype abnormality (HR 1.63, 95% CI 1.18-2.25) and monosomal karyotype (HR 1.49, 95% CI 1.05-2.12) were significantly associated with OS. Thus, the 3-year OS of allogeneic HCT was 29.8% in patients with CK-MDS, and we identified risk factors associated with poor OS.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndromes Mielodisplásicas
/
Transplante de Células-Tronco Hematopoéticas
Limite:
Humans
/
Male
Idioma:
En
Revista:
Br J Haematol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Japão